BIO 2026 | Alex Shneider | Curelab Oncology

Advanced clinical platforms are only as valuable as the lives they prolong. If an industry becomes too obsessed with its underlying technology, it risks losing sight of the true destination: the patient.

From Day 3 of BIO 2026, we sit down with Dr. Alex Shneider, the driving force behind Curelab Oncology. Moving fluidly between high-level medical philosophy and sharp, deadpan humor, Dr. Shneider outlines how comparative medicine serves as an essential framework for tackling oncology and inflammatory conditions across species lines.

Dr. Shneider joins the program to share the operational realities of running parallel human and animal health pipelines and explains why a "patient-first" mindset must dictate every single tool a biotech company builds.